S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) Competitors

$5.09
-0.10 (-1.93%)
(As of 05:19 PM ET)
Compare
Today's Range
$5.01
$5.21
50-Day Range
$4.86
$7.23
52-Week Range
$2.70
$15.89
Volume
91,314 shs
Average Volume
422,240 shs
Market Capitalization
$222.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.63

YMAB vs. CRMD, EBS, EGRX, TSVT, RENB, OMER, LFCR, ALXO, ALLK, and STOK

Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include CorMedix (CRMD), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX), 2seventy bio (TSVT), Renovaro Biosciences (RENB), Omeros (OMER), Lifecore Biomedical (LFCR), ALX Oncology (ALXO), Allakos (ALLK), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical preparations" industry.

Y-mAbs Therapeutics vs.

Y-mAbs Therapeutics (NASDAQ:YMAB) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

CorMedix has lower revenue, but higher earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs Therapeutics$65.27M3.47-$95.57M-$0.89-5.83
CorMedix$36.52K5,447.63-$29.70M-$0.86-4.22

Y-mAbs Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

In the previous week, Y-mAbs Therapeutics' average media sentiment score of 0.00 beat CorMedix's score of -0.27 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Y-mAbs Therapeutics Neutral
CorMedix Neutral

Y-mAbs Therapeutics presently has a consensus target price of $12.63, indicating a potential upside of 143.26%. CorMedix has a consensus target price of $12.33, indicating a potential upside of 244.51%. Given CorMedix's stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Y-mAbs Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Y-mAbs Therapeutics
2 Sell rating(s)
5 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.18
CorMedix
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Y-mAbs Therapeutics has a net margin of -45.96% compared to CorMedix's net margin of -45,003.03%. Y-mAbs Therapeutics' return on equity of -36.37% beat CorMedix's return on equity.

Company Net Margins Return on Equity Return on Assets
Y-mAbs Therapeutics-45.96% -36.37% -28.14%
CorMedix -45,003.03%-68.87%-61.41%

Y-mAbs Therapeutics received 105 more outperform votes than CorMedix when rated by MarketBeat users. Likewise, 59.04% of users gave Y-mAbs Therapeutics an outperform vote while only 50.00% of users gave CorMedix an outperform vote.

CompanyUnderperformOutperform
Y-mAbs TherapeuticsOutperform Votes
111
59.04%
Underperform Votes
77
40.96%
CorMedixOutperform Votes
6
50.00%
Underperform Votes
6
50.00%

45.5% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 35.0% of CorMedix shares are held by institutional investors. 21.5% of Y-mAbs Therapeutics shares are held by company insiders. Comparatively, 3.6% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Y-mAbs Therapeutics beats CorMedix on 10 of the 17 factors compared between the two stocks.


Get Y-mAbs Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YMAB vs. The Competition

MetricY-mAbs TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$226.39M$5.15B$4.31B$6.31B
Dividend YieldN/A2.64%2.49%5.88%
P/E Ratio-5.833.76117.5311.69
Price / Sales3.47158.002,877.5554.12
Price / CashN/A20.7386.35101.50
Price / Book2.083.733.744.73
Net Income-$95.57M$178.51M$121.32M$185.55M
7 Day Performance4.01%-4.82%-1.73%-2.90%
1 Month Performance-15.33%-6.02%-0.51%-3.95%
1 Year Performance-63.55%3.21%5.75%1.85%

Y-mAbs Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRMD
CorMedix
1.7702 of 5 stars
$3.99
+2.3%
$12.33
+209.1%
+14.2%$218.67M$36,519.00-4.6440Positive News
EBS
Emergent BioSolutions
2.2372 of 5 stars
$4.11
-2.6%
$27.75
+575.2%
-83.2%$212.93M$1.07B-0.342,500Short Interest ↓
EGRX
Eagle Pharmaceuticals
2.1669 of 5 stars
$16.29
+2.9%
$17.00
+4.4%
-45.0%$211.61M$316.61M13.81134Short Interest ↓
TSVT
2seventy bio
1.9905 of 5 stars
$4.16
-5.0%
$23.80
+472.1%
-76.6%$209.93M$147.25M-0.97425Gap Up
High Trading Volume
RENB
Renovaro Biosciences
0 of 5 stars
$3.26
-9.4%
N/AN/A$209.82MN/A0.0022Upcoming Earnings
News Coverage
Positive News
OMER
Omeros
1.9413 of 5 stars
$3.32
-3.5%
$8.00
+141.0%
-22.9%$208.68M$73.81M5.19196
LFCR
Lifecore Biomedical
1.2778 of 5 stars
$7.55
+1.1%
$9.50
+25.8%
N/A$228.93M$103.27M-2.25689
ALXO
ALX Oncology
1.8303 of 5 stars
$5.05
+1.8%
$21.00
+315.8%
-56.1%$207.82M$1.18M-1.5872
ALLK
Allakos
2.3739 of 5 stars
$2.38
-4.8%
$13.60
+471.4%
-61.3%$206.87MN/A-1.23123Positive News
Gap Up
STOK
Stoke Therapeutics
2.3127 of 5 stars
$5.22
-1.3%
$23.50
+350.2%
-70.9%$231.02M$8.84M-2.06117News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:YMAB) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -